The American Society of Clinical Oncology (ASCO) held its annual meeting from June 3-7, 2022. Visit the links below for research highlights from the meeting, including survey results about Black people’s attitudes about clinical trial participation.
ASCO 2022
- Breast Cancer Research Foundation: ASCO 2022: Metastatic Breast Cancer Treatment Updates
Trastuzumab Deruxtecan (Enhertu®) for HER2-Low MBC
- ASCO: Novel Antibody-Drug Conjugate Doubles Progression-Free Survival in MBC With Low HER2 Expression
- ASCO Post: Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low MBC
- Breastcancer.org (Podcast): Enhertu for HER2-Low Metastatic Breast Cancer
- MedPage Today: Trastuzumab Deruxtecan for HER2-Low Breast Cancer
Sacituzumab Govitecan (Trodelvy®) for Hormone Receptor-Positive MBC
- ASCO: Novel Agent Increases Progression-Free Survival for Patients With Hormone Receptor-Positive MBC
- ASCO Post (Video and Article): Dr. Lisa Carey and Dr. Hope Rugo on New Data for Sacituzumab Govitecan-hziy in Hormone Receptor-Positive MBC
BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement) Survey Results
- Metastatic Breast Cancer Alliance: BECOME Final Report
- ASCO: Increasing Black Patient Participation in MBC Clinical Trials
- Metastatic Breast Cancer Alliance: MBCA’s BECOME Poster Featured at 2022 ASCO Annual Meeting
- Metastatic Breast Cancer Alliance: BECOME Poster
- ASCO Post (Video and Article): Stephanie Walker on Increasing the Participation of Black People With MBC in Clinical Trials
- Practice Update: Black Patients With MBC Willing to Consider Clinical Trials
